Literature DB >> 27914657

Ulcerative colitis.

Ryan Ungaro1, Saurabh Mehandru2, Patrick B Allen3, Laurent Peyrin-Biroulet4, Jean-Frédéric Colombel5.   

Abstract

Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors. Patients with ulcerative colitis have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. Ulcerative colitis usually presents with bloody diarrhoea and is diagnosed by colonoscopy and histological findings. The aim of management is to induce and then maintain remission, defined as resolution of symptoms and endoscopic healing. Treatments for ulcerative colitis include 5-aminosalicylic acid drugs, steroids, and immunosuppressants. Some patients can require colectomy for medically refractory disease or to treat colonic neoplasia. The therapeutic armamentarium for ulcerative colitis is expanding, and the number of drugs with new targets will rapidly increase in coming years.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27914657      PMCID: PMC6487890          DOI: 10.1016/S0140-6736(16)32126-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  535 in total

Review 1.  The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

Authors:  Dana Rachel Berg; Jean-Frederic Colombel; Ryan Ungaro
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

2.  IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease.

Authors:  Lyssia Belarif; Richard Danger; Laetitia Kermarrec; Véronique Nerrière-Daguin; Sabrina Pengam; Tony Durand; Caroline Mary; Elise Kerdreux; Vanessa Gauttier; Aneta Kucik; Virginie Thepenier; Jerome C Martin; Christie Chang; Adeeb Rahman; Nina Salabert-Le Guen; Cécile Braudeau; Ahmed Abidi; Grégoire David; Florent Malard; Celine Takoudju; Bernard Martinet; Nathalie Gérard; Isabelle Neveu; Michel Neunlist; Emmanuel Coron; Thomas T MacDonald; Pierre Desreumaux; Hoa-Le Mai; Stephanie Le Bas-Bernardet; Jean-François Mosnier; Miriam Merad; Régis Josien; Sophie Brouard; Jean-Paul Soulillou; Gilles Blancho; Arnaud Bourreille; Philippe Naveilhan; Bernard Vanhove; Nicolas Poirier
Journal:  J Clin Invest       Date:  2019-04-02       Impact factor: 14.808

3.  Glucocorticoid receptor modulators CpdX and CpdX-D3 exhibit the same in vivo antiinflammatory activities as synthetic glucocorticoids.

Authors:  Guoqiang Hua; Naimah Zein; François Daubeuf; Pierre Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-21       Impact factor: 11.205

4.  Dysregulated Up-Frameshift Protein 1 Promotes Ulcerative Colitis Pathogenesis Through the TNFR1-NF-κB/MAPKs Pathway.

Authors:  Huatuo Zhu; Shujun Huang; Min Yue; Wenguo Chen; Chao Lu; Xinhe Lou; Chunxiao Li; Guodong Shan; Hongtan Chen; Xiaowei Xu; Guoqiang Xu; Lihua Chen
Journal:  Dig Dis Sci       Date:  2018-06-29       Impact factor: 3.199

5.  Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.

Authors:  Jean Lawton; Hamza Achit; Lieven Pouillon; Emmanuelle Boschetti; Béatrice Demore; Thierry Matton; Charlène Tournier; Martin Prodel; Laurent Peyrin-Biroulet; Francis Guillemin
Journal:  United European Gastroenterol J       Date:  2019-05-20       Impact factor: 4.623

6.  Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis.

Authors:  Siddharth Singh; James A Proudfoot; Parambir S Dulai; Ronghui Xu; Brian G Feagan; William J Sandborn; Vipul Jairath
Journal:  Clin Gastroenterol Hepatol       Date:  2019-05-18       Impact factor: 11.382

7.  Functional polymorphisms of the receptor for the advanced glycation end product promoter gene in inflammatory bowel disease: a case-control study.

Authors:  Rachele Ciccocioppo; Sara Bozzini; Elena Betti; Venerina Imbesi; Catherine Klersy; Lucia Sukovska Lakyova; Lukas Sukovsky; Jozef Benacka; Peter Kruzliak; Gino Roberto Corazza; Antonio Di Sabatino; Colomba Falcone
Journal:  Clin Exp Med       Date:  2019-06-07       Impact factor: 3.984

8.  Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease.

Authors:  Adam Tepler; Neeraj Narula; Richard M Peek; Anish Patel; Cyrus Edelson; Jean-Frederic Colombel; Shailja C Shah
Journal:  Aliment Pharmacol Ther       Date:  2019-06-05       Impact factor: 8.171

Review 9.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

10.  Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.

Authors:  Christopher Ma; William J Sandborn; Geert R D'Haens; Guangyong Zou; Larry W Stitt; Siddharth Singh; Ashwin N Ananthakrishnan; Parambir S Dulai; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Clin Gastroenterol Hepatol       Date:  2019-09-20       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.